MoonLake Immunotherapeutics
NASDAQMoonLake Immunotherapeutics reported earnings on August 10. Short sellers covered aggressively. The borrow market opened wide. Then options traders started buying puts at the fastest clip in three weeks. Three signals. Three different directions. Short interest fell 11.5% in a single day on August 11, dropping to 7.9% of free float — the lowest reading…
MLTX short interest jumps 23.2% in one week to 9.4% of free float, driven by recent insider selling and strong stock momentum amid clinical-stage biotech volatility.
Snapshot as of 23 Sept 2026
MoonLake Immunotherapeutics reported earnings on August 10. Short sellers covered aggressively. The borrow market opened wide. Then options traders started buying puts at the fastest clip in three weeks. Three signals.…
MoonLake Immunotherapeutics heads into Wednesday's earnings release carrying a visible insider selling overhang and a stock that has lost 15% in the past month alone. The most pointed signal ahead of the print is…
MoonLake Immunotherapeutics ends the week in retreat — down 8.2% to $19.47 — with insiders still distributing stock and the extreme options bullishness flagged last week having quietly unwound. The insider selling is…
MoonLake Immunotherapeutics heads into the week with a sharp contradiction at its core: options traders are the most bullish they have been all year, while the founders and CFO have been selling stock steadily into the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MLTX — free to start on ORTEX.
Sign up for free →Open MLTX on ORTEX